Glioblastomas (GBMs) are one of the most difficult cancers to treat. Their success in defying therapy relies in large part on their dynamic cellular heterogeneity and on their ability to subvert their environment, in particular to create an immune suppressive milieu. This project will address the role of the newly discovered communication vehicles in cancer, extracellular vesicles (EVs) which can carry RNA and protein as informational molecules. Our goal is to evaluate to what extent EVs produced by these tumors contribute to an immune suppressive environment through their interaction with tumor-associated macrophages and microglia (TAMs), and to what extent EVs produced by different genetic subtypes of gliomas, and the stem-like cells within these tumors, underlie to their ability to re-define themselves and escape therapy.
In Aim 1 we will assess EV-mediated information transfer between glioma tumors and microglia/macrophages in the tumor microenvironment and its effect on immune suppression.
In Aim 2 we will evaluate the role of EVs in modulating GBM stem-like cell (GSC) phenotypes and therapeutic resistance. Studies will use syngeneic mouse glioma models as well as human GBM stem-like neurosphere cultures and patient-derived xenograft in mouse models developed with Core C. We will generate an array of vectors to label cells with multiple luciferases and fluorescent proteins, as well as create capsules to contain tumor cells while allowing release of EVs and/or small molecules within the brain. FACS analysis and RNAseq will be used to define the transcriptome of different cell populations in the brain. Biofluids from mice, as well as from GBM patients (Core B), will be sent to Project 2 for protein analysis. Correlative analysis of mRNA/ protein contents and GBM genotypes will be assessed, as well as how EV contents reflect changes in GBM subtype and resistance to therapy. Our findings will be integrated with those of Project 3 in the context of preclinical evaluation of Gene- Mediated Cytotoxic Immunotherapy (GMIC) combined with immune checkpoint inhibition. Organizational oversight of rigor and reproducibility will be provided by Core A. Studies in this project will serve to inform the development of the projected clinical trial by elucidating how EVs influence and report on GBM status, and how they can be manipulated to improve this type of immunotherapy in the context of the GBM brain tumors.
The ability of RNA and protein in extracellular vesicles (EVs) derived from gliomas to alter the phenotype of tumors and contribute to immune suppression will be evaluated. Glioma-derived EVs in biofluids will also be explored as biomarkers in monitoring tumor status and response to therapy.
| Shao, Huilin; Im, Hyungsoon; Castro, Cesar M et al. (2018) New Technologies for Analysis of Extracellular Vesicles. Chem Rev 118:1917-1950 |
| Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766 |
| Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494 |
| Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906 |
| Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029 |
| Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384 |
| Lee, Kyungheon; Fraser, Kyle; Ghaddar, Bassel et al. (2018) Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano 12:494-503 |
| Reátegui, Eduardo; van der Vos, Kristan E; Lai, Charles P et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun 9:175 |
| Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235 |
| Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141 |
Showing the most recent 10 out of 223 publications
